Pricing Strategy Development
Starting with informed pricing assumptions at an early stage of product development is key to commercial success.
Setting – and achieving – the right price for your product can be challenging. Many variables come into play, and it is important to identify which ones are most relevant in a given situation.
RJW&partners work across all stages of a product’s development, using the most suitable approach and research methodologies.
Payer and KOL perspectives on innovative contracting agreements in haemophilia
Our client had developed innovative contracting designs for these coagulation factor products, and wished to test their feasibility with payers and key opinion leaders across the EU5, Sweden and the Netherlands.
READ THE CASE STUDY HERE
WHERE WE FIT IN
Developing an effective pricing strategy with RJW&partners
NAVIGATING COMPLEX ISSUES
Determining an appropriate price can be complex. In some cases, there may be no pricing benchmark at all – for example, a brand new therapy with no direct competitors, or launching into an emerging market.
In other cases, the product may have novel dosing features, or be used across several indications.
Products used across multiple positions in a treatment pathway may face different reimbursement levels.
Reference pricing across major global markets means the right launch sequence is critical – and can determine commercial success or failure.
HOW WE STAND OUT
We tailor our approach to your requirements and rapidly come up to speed thanks to the breadth of our existing knowledge.
We focus on applying the best methods to address the key issues for your product. We commit to delivering a clear, concise and comprehensive pricing strategy in agreed timeframes.
Pricing strategy development methodologies:
Desk research based on internal payer expertise.
Qualitative research based on interviews with external payers.
National or international payer Advisory Boards.
Preliminary health economic modelling.
Semi-quantitative pricing research with clinicians.
Evaluation of potential risk-sharing arrangements.
Pricing & market access recommendations for a product in alcohol dependence in Europe and Russia
Our client was the Global Pricing & Market Access Director for a new product in development for use in alcohol dependence.
This was a new area for the company; phase 3 had just been completed and HEOR arguments were still at an early stage.
While the product had some novel features in terms of dosing, it was going to enter an area where products were well established and access would be hard.